ABPI response to UK genomics strategy
The Department of Health and Social Care has published its National Genomic Healthcare Strategy, which sets out their aim to cement the UK as a global leader in genomics.
The UK has led the world in genomics, but if we want to maintain our place we need to build data infrastructure, skills and public trust ready for the next exciting decade. Dr Bryan Deane
The strategy outlines the government’s ambition for the genomics community to come together to create the most advanced genomic healthcare system in the world. It is split into three pillars: diagnosis and personalised medicine, prevention, and research.
It builds on previous UK successes including the 100,000 Genome Project. The venture discovered actionable findings for 1 in 4 rare disease patients, and around 50% of cancer cases contain the potential for a therapy or a clinical trial.
The value of genomics was demonstrated earlier this year with scientists sequencing the COVID-19 virus within weeks of discovery. A decade ago, this process would have taken months and may have even been impossible.
In response, Dr Bryan Deane, ABPI’s Director of New Medicines & Data Policy said:
“You only have to look at the recent successes of genomics to see how far we’ve come – and the enormous future potential it holds for patients in both the prevention and treatment of all diseases. The UK has led the world in genomics, but if we want to maintain our place we need to build data infrastructure, skills and public trust ready for the next exciting decade.
The ABPI and its members look forward to working with the Government, academia, and patient groups to further develop the National Genomic Healthcare Strategy and realise the full benefits of genomics for UK patients.
Last modified: 20 September 2023
Last reviewed: 20 September 2023